Alpha 2.0
Login Register
» Authors » Jennifer T Fox

Jennifer T Fox

Explore the profile of Jennifer T Fox including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 478
Followers 0
Related Specialties
Oncology
Biochemistry
Molecular Biology
Top 10 Co-Authors
Kyungjae Myung
Robert H Shoemaker
Shizuko Sei
Ronald A Lubet
Patrick J Stover
Clinton J Grubbs
Neha Mishra
Rama Kant
Chapla Agarwal
Rajesh Agarwal
Published In
J Biol Chem
Cancer Prev Res (Phila)
FEBS Lett
Mol Carcinog
Proc Natl Acad Sci U S A
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy of EGFR Inhibitors and NSAIDs Against Basal Bladder Cancers in a Rat Model: Daily vs. Weekly Dosing, Combining EGFR Inhibitors with Naproxen, and Effects on RNA Expression
Lubet R, Kumar A, Fox J, You M, Mohammed A, Juliana M, et al.
Bladder Cancer . 2024 Jul; 7(3):335-345. PMID: 38993610
Background: There are few effective treatments specifically aimed at basal bladder cancer. Objective: Female F344 rats administered N-butyl-N-(4-hydroxybutyl)-nitrosamine (OH-BBN) develop large invasive bladder cancers. We determined the efficacy of daily...
2.
Effect of nonsteroidal anti-inflammatory drugs (aspirin and naproxen) on inflammation-associated proteomic profiles in mouse plasma and prostate during TMPRSS2-ERG (fusion)-driven prostate carcinogenesis
Prasad R, Mishra N, Kant R, Fox J, Shoemaker R, Agarwal C, et al.
Mol Carcinog . 2024 Mar; 63(6):1188-1204. PMID: 38506376
Recent preclinical studies have shown that the intake of nonsteroidal anti-inflammatory drugs (NSAIDs) aspirin and naproxen could be an effective intervention strategy against TMPRSS2-ERG fusion-driven prostate tumorigenesis. Herein, as a...
3.
Differential Effect of Non-Steroidal Anti-Inflammatory Drugs Aspirin and Naproxen against (Fusion)-Driven and Non-Fusion-Driven Prostate Cancer
Raina K, Kandhari K, Kant R, Prasad R, Mishra N, Maurya A, et al.
Cancers (Basel) . 2023 Oct; 15(20). PMID: 37894421
The consumption of the non-steroidal anti-inflammatory drug (NSAID) aspirin is associated with a significant reduction in the risk of developing (fusion)-positive prostate cancer (PCa) compared to fusion-negative PCa in population-based...
4.
Primary Prevention and Interception Studies in RAS-Mutated Tumor Models Employing Small Molecules or Vaccines
Dragnev K, Lubet R, Miller M, Sei S, Fox J, You M
Cancer Prev Res (Phila) . 2023 Jul; 16(10):549-560. PMID: 37468135
Therapeutic targeting of RAS-mutated cancers is difficult, whereas prevention or interception (treatment before or in the presence of preinvasive lesions) preclinically has proven easier. In the A/J mouse lung model,...
5.
Treatment Strategies and Mechanisms Associated with the Prevention of NASH-Associated HCC by a Toll-like Receptor 4 Inhibitor
Kwan S, Slayden A, Coronado A, Marquez R, Chen H, Wei P, et al.
Cancer Prev Res (Phila) . 2022 Sep; 16(1):17-28. PMID: 36162136
Prevention Relevance: Means to prevent development of HCC or progression of small adenomas to HCC in patients with NASH are urgently needed to reduce the growing mortality due to HCC....
6.
Oral administration of TRAIL-inducing small molecule ONC201/TIC10 prevents intestinal polyposis in the mouse model
Madka V, De La Cruz A, Pathuri G, Panneerselvam J, Zhang Y, Stratton N, et al.
Am J Cancer Res . 2022 Jun; 12(5):2118-2131. PMID: 35693092
Colorectal cancer (CRC) incidence is rising globally. Hence, preventing this disease is a high priority. With this aim, we determined the CRC prevention potential of the TRAIL-inducing small molecule ONC201/TIC10...
7.
Characterization of stage-specific tumor progression in TMPRSS2-ERG (fusion)-driven and non-fusion-driven prostate cancer in GEM models
Raina K, Kant R, Prasad R, Kandhari K, Tomar M, Mishra N, et al.
Mol Carcinog . 2022 Apr; 61(7):717-734. PMID: 35452553
In the present study, we performed a comparative stage-specific pathological and molecular marker evaluation of TMPRSS2-ERG fusion and PTEN loss-driven (TMPRSS2-ERG. Pten ) versus non-fusion-driven prostate tumorigenesis (Hi-Myc) in mice....
8.
The HIV protease inhibitor, ritonavir, corrects diverse brain phenotypes across development in mouse model of DYT-TOR1A dystonia
Caffall Z, Wilkes B, Hernandez-Martinez R, Rittiner J, Fox J, Wan K, et al.
Sci Transl Med . 2021 Aug; 13(607). PMID: 34408078
Dystonias are a group of chronic movement-disabling disorders for which highly effective oral medications or disease-modifying therapies are lacking. The most effective treatments require invasive procedures such as deep brain...
9.
Effects of High-Fructose Diet . Teklad Diet in the MNU-Induced Rat Mammary Cancer Model: Altered Tumorigenesis, Metabolomics and Tumor RNA Expression
Kumar A, Lubet R, Fox J, Nelson W, Seifried H, Grubbs C, et al.
J Obes Chronic Dis . 2021 Apr; 5(1):67-78. PMID: 33834161
Epidemiology, clinical and experimental animal studies suggest high fructose diets are detrimental to metabolic status and may contribute to tumor development. This due to increased obesity and metabolic syndrome, known...
10.
Use of Biomarker Modulation in Normal Mammary Epithelium as a Correlate for Efficacy of Chemopreventive Agents Against Chemically Induced Cancers
Lubet R, Heckman-Stoddard B, Fox J, Moeinpour F, Juliana M, Shoemaker R, et al.
Cancer Prev Res (Phila) . 2019 Dec; 13(3):283-290. PMID: 31871222
In both estrogen receptor/progesterone receptor-positive (ER/PR) human breast cancer and in ER/PR cancers in the methylnitrosourea (MNU)-induced rat model, short-term modulation of proliferation in early cancers predicts preventive/therapeutic efficacy. We...